GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Price-to-Free-Cash-Flow

BCAL Diagnostics (ASX:BDX) Price-to-Free-Cash-Flow : N/A (As of Jun. 06, 2024)


View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Price-to-Free-Cash-Flow?

As of today (2024-06-06), BCAL Diagnostics's share price is A$0.125. BCAL Diagnostics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.02. Hence, BCAL Diagnostics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for BCAL Diagnostics's Price-to-Free-Cash-Flow or its related term are showing as below:

ASX:BDX's Price-to-Free-Cash-Flow is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 25.58
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

BCAL Diagnostics's Free Cash Flow per Share for the six months ended in Dec. 2023 was A$-0.00. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was A$-0.02.


BCAL Diagnostics Price-to-Free-Cash-Flow Historical Data

The historical data trend for BCAL Diagnostics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Price-to-Free-Cash-Flow Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23
Price-to-Free-Cash-Flow
- -

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial - - - - -

Competitive Comparison of BCAL Diagnostics's Price-to-Free-Cash-Flow

For the Diagnostics & Research subindustry, BCAL Diagnostics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BCAL Diagnostics's Price-to-Free-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where BCAL Diagnostics's Price-to-Free-Cash-Flow falls into.



BCAL Diagnostics Price-to-Free-Cash-Flow Calculation

BCAL Diagnostics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.125/-0.02
=N/A

BCAL Diagnostics's Share Price of today is A$0.125.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BCAL Diagnostics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.02.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

BCAL Diagnostics  (ASX:BDX) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


BCAL Diagnostics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


BCAL Diagnostics (ASX:BDX) Business Description

Traded in Other Exchanges
N/A
Address
Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.

BCAL Diagnostics (ASX:BDX) Headlines